|
CA2694139C
(en)
*
|
2007-07-31 |
2018-06-05 |
Affibody Ab |
Albumin binding polypeptide compositions
|
|
WO2010141329A1
(en)
*
|
2009-06-01 |
2010-12-09 |
Medimmune, Llc |
Molecules with extended half-lives and uses thereof
|
|
CN102811782A
(zh)
*
|
2010-03-08 |
2012-12-05 |
通用电气健康护理生物科学股份公司 |
免疫球蛋白G Fc区结合多肽
|
|
WO2011136361A1
(ja)
*
|
2010-04-30 |
2011-11-03 |
株式会社 三和化学研究所 |
生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
|
|
MX2013000314A
(es)
*
|
2010-07-09 |
2013-01-29 |
Affibody Ab |
Polipeptidos.
|
|
EP2601216B1
(en)
*
|
2010-08-02 |
2018-01-03 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
WO2012050923A2
(en)
|
2010-09-28 |
2012-04-19 |
Amylin Pharmaceuticals, Inc. |
Engineered polypeptides having enhanced duration of action
|
|
ES2630031T3
(es)
|
2010-09-28 |
2017-08-17 |
Aegerion Pharmaceuticals, Inc. |
Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
|
|
DK2643349T3
(da)
|
2010-11-26 |
2019-11-25 |
Molecular Partners Ag |
Designede repeat-proteiner, der binder til serumalbumin
|
|
CA2836873C
(en)
*
|
2011-05-21 |
2019-10-22 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
|
JP6006309B2
(ja)
*
|
2011-07-08 |
2016-10-12 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
|
|
ES2732475T3
(es)
*
|
2011-07-08 |
2019-11-22 |
Aegerion Pharmaceuticals Inc |
Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
|
|
WO2013126006A1
(en)
|
2012-02-20 |
2013-08-29 |
Swedish Orphan Biovitrum Ab (Publ) |
Polypeptides binding to human complement c5
|
|
US20150133373A1
(en)
*
|
2012-03-28 |
2015-05-14 |
Amylin Pharmaceuticals, Llc |
Transmucosal delivery of engineered polypeptides
|
|
US20160009767A9
(en)
*
|
2012-03-28 |
2016-01-14 |
Affibody Ab |
Oral administration
|
|
JP2020033372A
(ja)
*
|
2012-03-28 |
2020-03-05 |
アフィボディ・アーベー |
経口投与
|
|
MX355041B
(es)
|
2012-05-25 |
2018-03-28 |
Janssen Biotech Inc |
Dominios de union a albumina consenso no naturales.
|
|
CN111763247B
(zh)
*
|
2012-09-25 |
2024-09-13 |
阿菲博迪公司 |
白蛋白结合多肽
|
|
US9745350B2
(en)
|
2012-10-05 |
2017-08-29 |
Affibody Ab |
HER3 binding polypeptides
|
|
PL2912051T3
(pl)
*
|
2012-10-25 |
2018-08-31 |
Affibody Ab |
Sposób rozdzielania białek zawierających domenę wiążącą albuminę
|
|
AU2013336646B2
(en)
|
2012-10-25 |
2016-07-14 |
Affibody Ab |
ABD binding polypeptide
|
|
WO2014076179A1
(en)
|
2012-11-14 |
2014-05-22 |
Affibody Ab |
New polypeptide
|
|
USRE48805E1
(en)
|
2013-03-06 |
2021-11-02 |
Vision Global Holdings Ltd. |
Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
|
|
US9255262B2
(en)
|
2013-03-06 |
2016-02-09 |
Vision Global Holdings Ltd. |
Albumin-binding arginine deminase and the use thereof
|
|
HK1213194A1
(zh)
|
2013-03-14 |
2016-06-30 |
Daiichi Sankyo Co., Ltd. |
用於新型的结合蛋白质pcsk9
|
|
CN105247118A
(zh)
*
|
2013-03-14 |
2016-01-13 |
多伦多大学管理委员会 |
支架化肽文库以及其制备和筛选方法
|
|
ES2660912T3
(es)
|
2013-03-15 |
2018-03-26 |
Affibody Ab |
Nuevos polipéptidos
|
|
EP2986306A4
(en)
|
2013-04-18 |
2016-12-07 |
Armo Biosciences Inc |
METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
|
|
ES2688206T3
(es)
|
2013-06-17 |
2018-10-31 |
Armo Biosciences, Inc. |
Procedimiento de evaluación de la identidad y la estabilidad de proteínas
|
|
CN105658228B
(zh)
|
2013-08-28 |
2020-02-07 |
瑞典孤儿比奥维特鲁姆有限公司 |
结合人类补体c5的稳定多肽
|
|
MX367423B
(es)
|
2013-08-28 |
2019-08-21 |
Affibody Ab |
Polipeptidos de union a c5.
|
|
CN105658232A
(zh)
|
2013-08-30 |
2016-06-08 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素-10治疗疾病和病症的方法
|
|
EP3068425B1
(en)
|
2013-11-11 |
2021-01-27 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
WO2015091957A1
(en)
|
2013-12-20 |
2015-06-25 |
Affibody Ab |
Engineered albumin binding polypeptide
|
|
WO2015187295A2
(en)
|
2014-06-02 |
2015-12-10 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
|
MX370115B
(es)
|
2014-07-30 |
2019-12-02 |
Ngm Biopharmaceuticals Inc |
Dímeros que comprenden dos polipéptidos, útiles en el tratamiento de trastornos metabólicos.
|
|
SI3193930T1
(sl)
|
2014-09-17 |
2019-10-30 |
Affibody Ab |
Novi polipeptidi
|
|
WO2016060996A2
(en)
|
2014-10-14 |
2016-04-21 |
Armo Biosciences, Inc. |
Interleukin-15 compositions and uses thereof
|
|
AU2015336101A1
(en)
|
2014-10-22 |
2017-04-20 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
PL3212226T3
(pl)
|
2014-10-31 |
2020-11-02 |
Ngm Biopharmaceuticals, Inc. |
Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
|
|
CN108064235A
(zh)
|
2015-01-12 |
2018-05-22 |
阿菲博迪公司 |
Il-17a结合多肽
|
|
US10618970B2
(en)
|
2015-02-03 |
2020-04-14 |
Armo Biosciences, Inc. |
Method of treating cancer with IL-10 and antibodies that induce ADCC
|
|
WO2016179568A1
(en)
|
2015-05-06 |
2016-11-10 |
Protomer Technologies, Inc. |
Glucose responsive insulins
|
|
CA2986755A1
(en)
|
2015-05-28 |
2016-12-01 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
|
JP6882782B2
(ja)
|
2015-08-04 |
2021-06-02 |
デューク ユニバーシティ |
遺伝子コードされた本質的に無秩序な送達用ステルスポリマーおよびその使用方法
|
|
US10398761B2
(en)
|
2015-08-25 |
2019-09-03 |
Armo Biosciences, Inc. |
Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
|
|
US11752213B2
(en)
|
2015-12-21 |
2023-09-12 |
Duke University |
Surfaces having reduced non-specific binding and antigenicity
|
|
CN107022031A
(zh)
*
|
2016-01-29 |
2017-08-08 |
中国人民解放军军事医学科学院微生物流行病研究所 |
融合蛋白HSA1-Vβ1及其应用
|
|
WO2017210476A1
(en)
|
2016-06-01 |
2017-12-07 |
Duke University |
Nonfouling biosensors
|
|
EP3515928B1
(en)
|
2016-09-23 |
2026-01-28 |
Duke University |
Unstructured non-repetitive polypeptides having lcst behavior
|
|
CN107952080A
(zh)
*
|
2016-10-14 |
2018-04-24 |
中国科学院过程工程研究所 |
一种肿瘤靶向多肽-药物偶联衍生物、其制备方法及应用
|
|
WO2018132732A1
(en)
|
2017-01-12 |
2018-07-19 |
Duke University |
Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
|
|
WO2018213320A1
(en)
|
2017-05-15 |
2018-11-22 |
Duke University |
Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
|
|
WO2019006374A1
(en)
|
2017-06-30 |
2019-01-03 |
Duke University |
ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
|
|
US11077199B2
(en)
|
2017-08-09 |
2021-08-03 |
Massachusetts Institute Of Technology |
Albumin binding peptide conjugates and methods thereof
|
|
US20200239575A1
(en)
*
|
2017-10-06 |
2020-07-30 |
University Of Utah Research Foundation |
A fusion protein for targeted therapy of autoimmune disease
|
|
EP3691693A4
(en)
|
2017-10-06 |
2021-08-25 |
University Of Utah Research Foundation |
FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE
|
|
US12296018B2
(en)
*
|
2018-01-26 |
2025-05-13 |
Duke University |
Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same
|
|
EP3765496A1
(en)
|
2018-03-13 |
2021-01-20 |
Affibody AB |
Polypeptides based on a novel scaffold
|
|
EP3788343B1
(en)
|
2018-04-30 |
2024-03-27 |
Duke University |
Stimuli-responsive peg-like polymer-based drug delivery platform
|
|
EP3829622A4
(en)
|
2018-08-02 |
2022-05-11 |
Duke University |
DOUBLE AGONIST FUSION PROTEINS
|
|
WO2020051541A1
(en)
*
|
2018-09-07 |
2020-03-12 |
Duke University |
Nanoparticulate drug delivery systems
|
|
CN113710229B
(zh)
|
2019-02-25 |
2026-01-06 |
芝加哥大学 |
用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
|
|
US12441772B2
(en)
|
2019-06-04 |
2025-10-14 |
Molecular Partners Ag |
Designed ankyrin repeat domain with improved stability
|
|
US11512314B2
(en)
|
2019-07-12 |
2022-11-29 |
Duke University |
Amphiphilic polynucleotides
|
|
AU2020342349A1
(en)
|
2019-09-02 |
2022-03-03 |
Biotest Ag |
Factor VIII protein with increased half-life
|
|
EP3785726A1
(en)
|
2019-09-02 |
2021-03-03 |
Biotest AG |
Factor viii protein with increased half-life
|
|
US20220389066A1
(en)
|
2019-11-05 |
2022-12-08 |
Affibody Ab |
Polypeptides
|
|
WO2021165226A1
(en)
|
2020-02-17 |
2021-08-26 |
Biotest Ag |
Subcutaneous administration of factor viii
|
|
EP3878515A1
(en)
*
|
2020-03-09 |
2021-09-15 |
Hober Biotech AB |
Therapeutic agent targeting her2
|
|
WO2022098745A1
(en)
|
2020-11-03 |
2022-05-12 |
Indi Molecular, Inc. |
Compositions, delivery systems, and methods useful in tumor therapy
|
|
WO2022098743A1
(en)
|
2020-11-03 |
2022-05-12 |
Indi Molecular, Inc. |
Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
|
|
JP2023554258A
(ja)
|
2020-12-21 |
2023-12-27 |
アフィボディ アクティエボラーグ |
新規のポリペプチド
|
|
JP2024506070A
(ja)
|
2021-02-15 |
2024-02-08 |
アフィボディ アクティエボラーグ |
新規ｈｅｒ２結合ポリペプチド
|
|
EP4476247A1
(en)
|
2022-02-08 |
2024-12-18 |
Affibody AB |
Protein z variants binding thymic stromal lymphopoietin and their medical use
|
|
WO2023225534A1
(en)
|
2022-05-18 |
2023-11-23 |
Protomer Technologies Inc. |
Aromatic boron-containing compounds and related insulin analogs
|
|
TW202416938A
(zh)
|
2022-08-10 |
2024-05-01 |
日商興和股份有限公司 |
親和體微胞(affibody micelle)藥物複合體
|
|
JP2026506075A
(ja)
|
2023-02-17 |
2026-02-20 |
アブリンクス エン．ヴェー． |
新生児型ｆｃ受容体に結合するポリペプチド
|
|
WO2024227930A1
(en)
|
2023-05-04 |
2024-11-07 |
Affibody Ab |
New polypeptide
|
|
WO2025073871A1
(en)
|
2023-10-03 |
2025-04-10 |
Bicycletx Limited |
Bicyclic peptide ligand complexes specific for tfr1
|
|
WO2025158010A1
(en)
|
2024-01-25 |
2025-07-31 |
Affibody Ab |
Her2-binding polypeptide
|
|
CN121041473A
(zh)
*
|
2024-05-29 |
2025-12-02 |
烟台蓝纳成生物技术股份有限公司 |
一种双功能性融合蛋白、放射性核素标记物及其应用
|
|
CN118666961B
(zh)
*
|
2024-08-23 |
2024-11-26 |
通化安睿特生物制药股份有限公司 |
人白蛋白特异结合多肽及其应用
|